AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 21 min read$NRIX

Ring Christine sold $134K of NRIX

Ring Christine (Chief Legal Officer) sold 5,786 shares of Nurix Therapeutics, Inc. (NRIX) at $23.19 ($0.13M total) on 2026-10-02 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Ring Christine
Published Oct 2, 2026, 9:21 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 2, 2026, 9:23 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$NRIX
Neutral
medium confidence
Mentioned
$NRIX
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NRIXNeutralLow
01

Why it matters

The disclosed sale is modest and unlikely to move the stock significantly, but it provides transparency for investors monitoring insider behavior.

02

Market read

A routine insider sale with limited material impact; useful for compliance monitoring but low trading relevance.

03

What to watch

The insider's remaining stake remains sizable; no change in control or strategic direction.

Relevance 3/10Novelty 3/10Timing: same day filing

Background

Form 4 filing discloses insider transactions required by the SEC; such filings are primary sources of corporate insider activity.

Company-level read

Ticker impact

$NRIXNeutralMedium confidence
Context

Chief Legal Officer sold 5,786 shares for $134,149 via a 10b5-1 plan, reducing her stake to 9,110 shares.

Expected impact

likely slight pressure as the market prices in the insider sell

Evidence & confidence

C-level insider sale of $134k is modest; investors may view it as routine, limiting price effect.

Market effects

Sector

Minimal impact on the biotech sector; typical insider transaction.

Regional

None

Global

None

Counterpoint

What could challenge this read

The sale could be unrelated to company fundamentals and may be a portfolio rebalancing, not a negative signal.

Key entities

  • Company
    Nurix Therapeutics, Inc.

    Biopharma company developing targeted protein degradation therapies.

  • Person
    Ring Christine

    Chief Legal Officer of Nurix Therapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

NRIX insider trading history →

Related articles

OCT 13
$NRIXMedAI 8/10

Nurix Therapeutics 3Q 2026: Revenue $673.1M, EPS $4.73— 10-Q Summary

Nurix Therapeutics reported Q3 2026 revenue of $673.1M, up from $7.9M YoY, driven by Roche license revenue. Net income was $549.8M, a $636.2M swing from a loss last year. Diluted EPS was $4.73. The company advanced clinical trials and expanded partnerships with Roche, Gilead, Sanofi, and Pfizer, receiving $1.2B to date with up to $7.2B in potential milestones and royalties.

tradingview.com2 min
OCT 13
$NRIXHighAI 8/10

Nurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Nurix Therapeutics, Inc. (NRIX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 [Nurix logo] Nurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update Dosed first patient in registrational Phase 3 DAYBreak CLL-306 trial comparing bexobrutideg with pirtobrutinib in relapsed/refractory CLL/SLL Advanced bexobruti

SEC EDGAR 8-K2 min